VIVUS, Inc.
1172 Castro Street
Mountain View
California
94040
United States
Tel: 650-934-5200
Fax: 650-934-5389
Website: http://www.vivus.com/
Email: ir@vivus.com
428 articles about VIVUS, Inc.
-
VIVUS Provides Update on Pipeline and Program Milestones
1/8/2024
VIVUS LLC announced pipeline updates and program milestones.
-
New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure
11/28/2023
VIVUS LLC announced positive topline data from a post-marketing study to evaluate the effect of QSYMIA® on 24-hour ambulatory blood pressure .
-
FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
7/20/2022
VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index (BMI) in the 95th percentile or greater standardized for age and sex.
-
VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization
12/11/2020
VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “ Plan ”). The Bankruptcy Court approved the disclosure statement and solicitation procedures and con
-
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
7/7/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing.
-
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
6/2/2020
VIVUS, Inc., a biopharmaceutical company, announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P., which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes.
-
VIVUS Reports First Quarter 2020 Financial Results
5/6/2020
VIVUS, Inc., a biopharmaceutical company, reported financial results for the quarter ended March 31, 2020 and provided a business update.
-
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
5/1/2020
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020.
-
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
5/1/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of
-
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4/3/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million
-
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4/1/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 3
-
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
3/31/2020
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19
-
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
3/3/2020
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter and fiscal year ended December 31, 2019 and provided a business update.
-
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
3/2/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of patient enrollment in a Phase 4 clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate extended-release) capsules CIV in adolescents between the ages of 12 and 17 years who are obese (NCT# 03922945).
-
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
2/18/2020
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020.
-
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
2/5/2020
VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE® (pancrelipase) Delayed Release Capsules that extends the shelf life to 36 months across all PANCREAZE dosages.
-
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
1/7/2020
Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia
-
VIVUS to Present at Biotech Showcase on January 13, 2020
1/2/2020
The conference will be held at the Hilton San Francisco Union Square.
-
VIVUS Adopts Stockholder Rights Plan
12/31/2019
VIVUS will issue a dividend of one right for each share of its common stock held by stockholders of record as of the close of business on January 13, 2020.
-
VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
12/18/2019
Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents